Anthropic has launched a dedicated scientific research product called Claude Science while simultaneously renewing access to its Fable 5 and Mythos 5 models, according to a report from MobiHealthNews. The announcements arrive as the AI company moves to deepen its footprint in pharmaceutical research and other science-intensive industries, where demand for high-capability reasoning models has been growing steadily.
What Claude Science Brings to Research
Claude Science is positioned as a specialized offering built on top of Anthropic's existing model infrastructure, tailored for tasks common in drug discovery, clinical research, and academic science. The product is designed to handle complex data interpretation, literature synthesis, and hypothesis generation at a level the company says goes beyond general-purpose AI assistants. As detailed in earlier coverage, Anthropic launched Claude Science specifically to target the pharma market, where it sees a clear revenue opportunity among large research organizations.
Key Facts
- Anthropic has launched Claude Science, a product aimed at scientific and pharmaceutical research workflows.
- Access to Fable 5 and Mythos 5 has been renewed following a period of restricted availability.
- The announcements were reported by MobiHealthNews, which covers health technology and medical AI.
- Fable 5 and Mythos 5 are among the most capable models in Anthropic's current lineup.
- The moves reflect Anthropic's broader strategy to expand into specialized professional verticals.
The renewal of Fable 5 and Mythos 5 access is equally notable. Both models had been made unavailable to certain users following regulatory pressure. Anthropic had disabled Fable 5 and Mythos 5 after a U.S. export control order raised questions about how advanced AI models could be distributed internationally. That disruption affected customers and triggered legal action, with at least one enterprise user pursuing a lawsuit over the loss of access.
Restoring access to Fable 5 and Mythos 5 while introducing a science-focused product shows Anthropic is pushing forward on multiple fronts, even as it navigates a complex regulatory environment.MobiHealthNews
The Bigger Picture for Anthropic's Model Strategy
These developments fit a pattern that has emerged over the past several months. Anthropic launched Fable 5 and Mythos 5 as its most powerful models to date, with Mythos in particular representing a class of model designed for long-horizon reasoning tasks. The temporary loss of access to those models was a setback for enterprise customers who had built workflows around them. Restoring that access, alongside the debut of Claude Science, suggests the company has resolved enough of the regulatory uncertainty to move forward.
For health and life sciences organizations, the combination of Claude Science and renewed access to high-end models like Fable 5 and Mythos 5 could open up more ambitious use cases. Research teams that need to process large volumes of scientific literature, model molecular interactions, or assist with clinical trial design now have more options within a single vendor's ecosystem. Claude's model family is now broader and more specialized than it was even six months ago, which gives enterprise buyers more flexibility when selecting a tier that fits their needs and compliance requirements.
The news also comes at a moment when Anthropic faces intensifying competition from OpenAI, Google DeepMind, and a growing field of specialized scientific AI startups. Carving out a distinct position in pharmaceutical and academic research is one way the company can differentiate on more than raw benchmark performance. Whether Claude Science gains meaningful traction will depend on how well it integrates into existing research infrastructure and whether it can demonstrate measurable value in real-world workflows rather than controlled demonstrations.
More details on pricing, availability, and the specific capabilities of Claude Science are expected as Anthropic continues to roll out the product to early access partners.
